DLC1 and neoplasm: In addition, treatment with a CUL-4A inhibitor or a proteasome inhibitor can substitute functionally for EZH2 inhibition both in increasing the steady-state level of DLC1 protein and in cooperating with the two kinase inhibitors for tumor treatment.